We also verified that patients with relatively high MAP17 expression in tumor tissues had relatively high rates of recurrence-free survival and that MAP17 affects cell migration and invasion, metastasis, and clinical outcomes in patients with OSCC. The gene discussed is PDZK1IP1; the disease is neoplasm.